The role of IL-4+ memory T cells in SARS-CoV-2 booster vaccination
Vaccines effectively stimulate protective immune responses in healthy individuals, but the precise roles of germinal center (GC) and follicular helper T (TFH) cells in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine responses are not fully understood. This study used a conditional loss-of-function mouse model to investigate antibody responses to the Wuhan spike protein, specifically eliminating newly developed TFH cells during either the primary or memory phase. Our findings demonstrated that TFH-mediated GC responses are essential for primary vaccination. However, after booster immunization, memory B-cell responses were effectively regulated through extrafollicular mechanisms, independent of TFH cells. Ablating IL-4 receptor signaling in B cells attenuated antibody production in both the primary and memory phases, highlighting the critical role of IL-4 for optimal humoral immunity. We identified a unique population of IL-4-expressing memory T (IL-4+Tm) cells, characterized by CD27, GATA3, and IRF4 expression, that is strongly associated with these extrafollicular memory B-cell responses, capable of neutralizing SARS-CoV-2 variants. Furthermore, Omicron-based booster immunization recovered the immunity against emerging variants under TFH-deficient conditions. These results suggest that IL-4+Tm cells are an alternative pathway to sustain memory responses when GC function is impaired, particularly in immunocompromised states. Our study advances the understanding of memory T-cell-mediated humoral responses to SARS-CoV-2, offering insights for future vaccine strategies.
Authors
- Yosie Suzuki
- Rina Hashimoto (ORCID: https://orcid.org/0000-0002-7174-4563)
- Yuichiro Yamamoto (ORCID: https://orcid.org/0000-0003-1992-1806)
- Takanori Sasaki (ORCID: https://orcid.org/0000-0001-9720-0698)
- Yasuyo Harada (ORCID: https://orcid.org/0009-0007-9785-3809)
- Masayoshi Fukasawa (ORCID: https://orcid.org/0000-0002-0702-0691)
- Kazuo Takayama (ORCID: https://orcid.org/0000-0002-1132-2457)
- Hideki Ueno (ORCID: https://orcid.org/0000-0001-7747-0738)
- Takaji Wakita
- Tatsuya Yamamoto (ORCID: https://orcid.org/0000-0003-4297-6354)
- Masato Kubo
- Sewon Ki
- Kohji Noguchi (ORCID: https://orcid.org/0000-0002-9080-0807)
- Haruhiko Koseki (ORCID: https://orcid.org/0000-0001-8424-5854)
- Jumana Khalil
- Kosuke Miyauchi (ORCID: https://orcid.org/0000-0002-2349-6665)
- Manabu Nakayama (ORCID: https://orcid.org/0009-0001-0488-1664)
- Masashi Matsuda
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Tokyo Medical University (JP)
- Tokyo University of Science (JP)
- Kyoto University (JP)
- National Institute of Infectious Diseases (JP)
- Kazusa DNA Research Institute (JP)
- Kyoto University Hospital (JP)
- RIKEN Center for Integrative Medical Sciences (JP)
- The University of Tokyo (JP)
- Showa Pharmaceutical University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- International Immunology
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1093/intimm/dxaf051
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00